The role of triptorelin (Diphereline) in the treatment of prostate cancer
https://doi.org/10.17650/1726-9776-2008-4-4-53-56
Abstract
Efficacy and safety issues of triptorelin (Diphereline) use in the treatment of patients with prostate cancer are addressed. Several clinical studies of efficacy of treatment with triptoreline both in mono-regimen and combined with other drugs are discussed.
About the Author
B. P. Matveyev
State Enterprise N.N. Blokhin Russian Cancer Research Center of Russian Academy of Medical Sciences
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Аксель Е.М. Заболеваемость злокачественными новообразованиями мочевых и мужских половых органов в России в 2003 г. Онкоурология 2005;(1):6—9.
2. Minkov N.K., Zozikov B.I., Yaneva Z., Uldry P.A. A phase II trial with new triptorelin sustained release formulations in prostatic carcinoma. Int Urol Nephrol 2001;33(2):379—83.
3. Bouchot O., Soret J.Y., Jacqmin D. et al. Three-month sustained-release form of triptorelin in patients with advanced prostatic adenocarcinoma: results of an open pharmacodynamic and pharmacokinetic multicenter study. Horm Res 1998;50(2):89—93.
4. Klippel K.F., Winkler C.J., Jocham D. et al. Effectiveness and tolerance of 1 dosage forms (subcutaneous and intramuscular) of decapeptyl depot in patients with advanced prostate carcinoma. Urologe A 1999;38(3):270—5.
5. Gonzalez-Barcena D., Perez-Sanchez P.L., Graef A. et al. Inhibition of the pituitary-gonadal axis by a single intramuscular administration of D-Trp-6-LH-RH (decapeptyl) in a sustained-release formulation in patients with prostatic carcinoma. Prostate 1989;14(4):291—300.
6. Labrie F., Dupont A., Belanger A. et al. Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations. Br Med J (Clin Res Ed) 1985 10;291(6492):369—70.
7. Seppelt U., Bertermann H., Saerbeck C. Decapeptyl (D-Trp6-LH-RH) in the therapy of prostatic cancer with reference to the intramuscular administration of a depot preparation. Urologe A 1986;25(5):298—301.
8. Boccardo F., Decensi A., Guarneri D. et al. Long-term results with a long-acting formulation of D-TRP-6 LH-RH in patients with prostate cancer: an Italian prostatic cancer project (P.O.N.CA.P.) study. Prostate 1987;11(3):243—55.
9. Roger M., Duchier J., Lahlou N., Schally A.V. Treatment of prostatic cancers by periodic administration of a delayedrelease preparation of D-Trp(6)-LHRH. Ann Urol (Paris) 1986;20(2):109—12.
10. Dupont A., Cusan L., Gomez J.L. et al. Combination therapy with flutamide and the LHRH agonist [D-Trp6, des-Gly-NH(2)10]LHRH ethylamide in stage C prostatic carcinoma. Br J Urol 1993;72(5 Pt 1):629—34.
11. Steg A., Chiche R., Boccon-Gibod L., Debre B. Treatment of advanced prostatic cancer with a gonadorelin agonist, D-Trp6-LHRH. 41 cases. Presse Med 1985;14(40):2045—8.
12. Gonzalez-Barcena D., Perez-Sanchez P., Ureta-Sanchez S. et al. Treatment of advanced prostatic carcinoma with D-Trp-6-LH-RH. Prostate 1985;7(1):21—30.
13. Mathe G., Misset J.L., Vovan M.L., Machover D. Advanced cancer of the prostate. Treatment with an LH-RH agonist, D-Trp-6-LH-RH. Bull Cancer 1986;73(1):31—5.
14. Parmar H., Edwards L., Phillips R.H. et al. Orchiectomy versus long-acting D-Trp-6-LHRH in advanced prostatic cancer. Br J Urol 1987;59(3):248—54.
15. Mathe G., Schally A.V., Comaru-Schally A.M. et al. Phase II trial with D-Trp-6-LH-RH in prostatic carcinoma: comparison with other hormonal agents. Prostate 1986;9(4):327—42.
16. Maillefert J.F., Sibilia J., Michel F. et al. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999;161(4):1219—22.
Review
For citations:
Matveyev B.P. The role of triptorelin (Diphereline) in the treatment of prostate cancer. Cancer Urology. 2008;4(4):53-56. (In Russ.) https://doi.org/10.17650/1726-9776-2008-4-4-53-56
Views:
331
Email this article 